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Statement for debate
Antibiotic stewardship programs improve patient out-
comes and cost-eﬀ  ectiveness in critically ill patients in 
the ICU.
Introduction
Antibiotic stewardship programs are multidisciplinary 
initiatives whose primary aim is to optimize antibiotic 
usage. Th   e Infectious Disease Society of America (IDSA) 
and the Society for Health Care Epidemiology of America 
(SHEA) published guidelines for antimicrobial steward-
ship in 2007 aimed at providing information on how to 
establish such programs within health care institutions 
[1]. Because antibiotics are used heavily in the ICU, 
stewardship programs appear particularly applicable to 
this setting. Antimicrobial stewardship is broadly deﬁ  ned 
as a practice that ensures the optimal selection, dose and 
duration of antimicrobials and leads to the best clinical 
outcome for the treatment or prevention of infection 
while producing the fewest possible side eﬀ  ects and the 
lowest risk for subsequent resistance [2]. Antimicrobial 
stewardship programs may contain a variety of inter-
ventions that are complementary to eﬀ  ective infection 
prevention and control programs.
Inappropriate antimicrobial usage is a signiﬁ  cant 
problem, with approximately 50% of antimicrobial usage 
being unnecessary or suboptimal in hospital, community 
or ambulatory settings [3,4]. A recent study showed that 
approximately 20% of patients admitted to the ICU with 
Clostridium diﬃ   cile-associated diarrhoea were receiving 
antibiotics without any obvious evidence of infection, 
with an accompanying 28% in-hospital mortality [5]. As a 
consequence of indiscriminate antibiotic use, there are 
reported increases in the incidence of infections caused 
by resistant organisms. A signiﬁ   cant correlation was 
demonstrated between the increase in ﬂ  uoroquinolone 
prescriptions in Canada from 0.8 to 5.5 per 100 persons 
per year and increased ciproﬂ  oxacin-resistant Streptococcus 
pneumoniae from 0% to 1.7% [6]. Twelve percent of 
patients previously exposed to piperacillin-tazobactam 
were colonized with strains of enterobacteriaceae resis-
tant to this antibiotic [7] and the use of third generation 
cephalosporins is associated with higher rates of 
vancomycin-resistant enterococci and extended-spectrum 
β-lactamase-producing organisms [8]. Anti  microbial 
resistance emerging in response to the selective pressure 
exerted by antibiotics is also a clinical phenomenon, with 
outbreaks of antibiotic-resistant Pseudomonas aeuroginosa
and  Acinetobacter baumanii-calcoaceticus occurring in 
ICUs, where a huge antimicrobial pressure is present 
[9-11].
Although they are often life-saving, antibiotics can also 
cause serious harm to patients, including Clostridium 
diﬃ   cile    -associated diarrhoea, antibiotic-resistant infec-
tions and invasive candidiasis [12-14]. Antibiotics also 
result in dangerous drug interactions, life-threatening 
hypersensitivity reactions, nephrotoxicity, and QT pro-
longation, to name a few. Inappropriate antibiotic use 
also contributes to rising drug and hospitalisation costs, 
and the need to preserve our current antibiotic arsenal 
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antibiotic development [15].
Pro: There is justifi  cation for implementing 
antibiotic stewardship programs in the ICU
Clinicians have long been aware of the risks of antibiotic 
resistance associated with inappropriate antibiotic use, 
but nonetheless very few eﬀ  ective antibiotic policies have 
been implemented, and the problem appears to be even 
worsening [16]. Th  e costs associated with antibiotic 
usage are also escalating, with systemic antibiotics being 
the single most costly drug class over the past decade in 
non-federal hospitals in the United States. In 2007, 
systemic antibiotics accounted for 11.2% of the pharmacy 
budget of non-federal hospitals [17]. In addition to direct 
pharmacy costs, hospitalisation and other infrastructure 
costs are also increased, ultimately resulting in a greater 
strain on the healthcare system. Saving antibiotics will 
save money, and there are a variety of methods to do so.
Education is the cornerstone of any antibiotic steward-
ship program, with prescriber education and imple men-
tation of guidelines and clinical pathways improving 
antimicrobial prescribing behaviour. For example, studies 
using algorithms to shorten the course of antimicrobial 
therapy in ventilator-associated pneumonia led to signiﬁ  -
cantly lower antimicrobial therapy usage with reduction 
in costs, antimicrobial resistance, and super-infections 
without adversely aﬀ  ecting the length of stay or mortality 
[18,19]. Th   e absence of formal antimicrobial stewardship 
training programs for infectious diseases fellows, board-
certiﬁ  ed physicians, and pharmacists has recently been a 
challenge to the education imperative, however [20].
Preauthorisation (also known as formulary restriction) 
requires approval by a pharmacist or physician prior to 
clinical use of an antimicrobial. Although preauthori  za-
tion is thought to be the most eﬀ   ective method of 
controlling antimicrobial use, it does not alter the 
duration of therapy or the decision to give or withhold 
antibiotics. Th  e main beneﬁ   ts of this strategy are the 
supervision of antibiotic use by experts and substantial 
cost savings (with some studies demonstrating cost 
savings upwards of US$800,000) [21,22].
Th   rough prospective audit with interaction and 
feedback, antimicrobial use is reviewed after antimicro-
bial therapy has been initiated and recommendations are 
made with regard to their appropriateness in terms of 
selection, dose, route and duration. Prospective audit 
with feedback avoids delays in initiation of therapy and 
maintenance of prescribers’ autonomy, and can be imple-
mented in health care facilities of varying sizes [23,24]. A 
large teaching hospital reported a 37% reduction in the 
number of days of unnecessary antibiotics use by 
decreasing the duration of treatment and by reducing 
new starts [25]. In another study, antimicrobial suggestions 
from an infectious disease fellow and a clinical pharma-
cist resulted in 1.6 fewer days of parenteral therapy and 
cost savings with no adverse eﬀ  ects on clinical response 
[23]. Another study demonstrated a sustained decrease in 
parenteral antibiotics over a 7-year period following 
introduction of a prospective audit with interaction and 
feedback [26].
Multiple studies using healthcare information tech-
nology, such as computer-assisted decision support 
designed to provide treatment recommendations, have 
shown signiﬁ  cant reductions in the use of antibiotics and 
greater de-escalation to narrow-spectrum antimicrobials. 
Improvements in cost and eﬃ   ciency of existing steward-
ship programs, and improved physician knowledge 
regard  ing treatment and pathogen prediction were also 
noted [27-29]. In addition to improving antimicrobial use 
and patient care (including tracking of antibiotic resis-
tance patterns), such systems can improve surveil  lance of 
hospital-acquired infections and adverse drug events 
when compared to manual surveillance methods [30,31]. 
In a 15-month study using a web-based antimicrobial 
approval system linked to national antibiotic guidelines, a 
sustained reduction in third-generation cephalosporin 
prescriptions were accompanied by increased concor-
dance with antibiotic guidelines [32]. Th  ese  beneﬁ  ts have 
also been noted in an ICU-based study, where 
investigators used computerised anti-infective programs 
and were able to document signiﬁ  cant reductions in the 
use of excessive drug dosage, adverse drug events and 
length of hospital stay and costs [33].
Standardized pre-printed or computer-generated 
physician order sets can improve the eﬃ   ciency  of 
antibiotic stewardship programs. In a study looking into 
their beneﬁ  ts in the management of patients with septic 
shock in an emergency department, order sets were 
found to improve initial ﬂ  uid resuscitation, use of appro-
priate antibiotics and 28-day mortality [34]. A recent 
study to evaluate the hospital-wide impact of a standard-
ized order set for the management of severe bacteraemic 
sepsis has shown that a greater number of patients 
received appropriate initial antibiotic therapy with 
decreased incidence of organ failure and improved 
survival [35].
A survey of 670 US hospitals found that implementa-
tion of guideline-recommended practices to control 
antimicrobial use and optimize the duration of empirical 
therapy was associated with less antimicrobial resistance, 
including methicillin-resistant Staphylococcus aureus, 
vanco  mycin-resistant enterococci, ﬂ  uoroquinolone-
resistant  Escherichia coli and ceftazidime-resistant 
Klebsiella species [36]. Given the relationship between 
antimicrobial use and antimicrobial resistance, anti-
microbial stewardship appears to be a logical ﬁ  rst step in 
the eﬀ  ort to control antimicrobial resistance.
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been the subject of a recent Cochrane systematic review, 
examining 66 studies from 1980 to 2003 [37]. Th  e  main 
interventions analyzed in the review were targeted to 
decrease treatment (57 studies), increase treatment 
(6  studies) or both (3 studies). Th  e  interventions 
addressed the antibiotic regimen (61 studies), the 
duration of treatment (10 studies), the timing of ﬁ  rst dose 
(6 studies), or the decision to prescribe antibiotics 
(1 study). Optimization of antibiotic use was seen in 81% 
of the studies aimed at improving antimicrobial 
utilization. Signiﬁ  cant improvements in microbiological 
outcome (for example, prevalence of antibiotic-resistant 
bacteria) and clinical outcomes (for example, mortality 
and length of hospital stay) were also noted in some 
studies. Recent observational studies (subsequent to the 
Cochrane review) have demonstrated that reducing 
antimicrobial pressure correlates with improved anti-
microbial susceptibility of pathogens [38,39].
Antimicrobial stewardship programs using the methods 
described above will promote the optimal use of anti-
microbial therapy, leading to the best clinical outcome 
for patients. Th  e relative paucity of outcome data 
demonstrating the beneﬁ  ts of antimicrobial stewardship 
is likely due to its infancy: antimicrobial stewardship 
programs today are where infection control programs 
were roughly 30 years ago [40,41]. Because antimicrobials 
are widely prescribed in the ICU, with an apparent 
mortality beneﬁ  t with appropriate therapy [42], using the 
best available methods to optimize their use through 
antimicrobial stewardship is crucial.
Con: The evidence for eff  ectiveness of 
antimicrobial stewardship is lacking
Despite the publication of guidelines for improving the 
use of antimicrobial agents in the United States, a great 
deal of scepticism about the eﬀ  ectiveness and accepta-
bility of antimicrobial stewardship programs persists. In 
a survey conducted by the United States Centers for 
Disease Control and Prevention’s National Nosocomial 
Infections Surveillance Systems, only 40% of selected 
hospitals had antibiotic restriction policies and 60% used 
stop orders [43]. Antimicrobial stewardship programs are 
also 50% less likely to be implemented in community 
hospitals compared to academic hospitals [44]. Two years 
after the publication of the IDSA/SHEA antibiotic 
steward  ship guidelines [1] only 48% of survey respon-
dents stated that their hospital had a program [41].
Reduction in the incidence of bacterial resistance is 
touted as the main advantage of antimicrobial steward-
ship programs, but lacks scientiﬁ  c evidence to support it. 
In a recent survey of 33 US hospitals, there was no 
signiﬁ   cant correlation between antibiotic guideline 
adherence by physicians and resistance rates [45]. 
Antibiotic use in ICUs may be the consequence rather 
than the cause of resistance, and there is a risk that 
stewardship, with its emphasis on decreased antibiotic 
use, could lead to a substantial increase in patient risk. It 
is also important to note that neither the published 
guidelines nor the important stewardship articles identify 
safety as an endpoint.
Another potentially adverse consequence of antibiotic 
restriction is the emergence of new resistance patterns 
replacing the old ones. A study documenting the 
introduction of new guidelines that restricted cephalo-
sporin use was primarily aimed at reducing the incidence 
of cephalosporin-resistant Klebsiella spp. Even though 
the primary aim was achieved, this occurred at the 
expense of increased imipenem usage with the subse-
quent increase in incidence of imipenem-resistant 
P.  aeuroginosa by about 69% [46]. Th  us, formulary 
restriction does not necessarily prevent the potential 
overuse of available broad spectrum antibiotics in routine 
practice [47]. Rather, a signiﬁ   cant change in clinical 
thinking to reduce our dependence on and abuse of 
antibiotics is needed.
Antimicrobial stewardship programs form only one 
strategy for minimizing the incidence of resistance, and 
must partner with infection control measures, including 
surveillance, outbreak investigation, disinfection and 
sterilization, and environmental hygiene. Of the studies 
reported to be beneﬁ  cial, it remains unclear as to whether 
the reported improvements in resistance rates are related 
to antimicrobial stewardship programs, infection control 
measures or both.
Although healthcare information technology is believed 
to be a key component of antimicrobial stewardship 
programs, detailed information on the resources required 
to implement and maintain these sophisticated computer 
programs is not widely available. It is also not clear 
whether the reported cost-eﬀ  ectiveness of many of these 
stewardship programs takes into account the overall cost 
of these interventions above and beyond the pharmacy-
related costs and expenses associated with development 
and distribution of educational materials.
Another challenge to implementing antimicrobial 
steward  ship in the ICU deals with the conﬁ  dence inten-
sivists have in the clinical judgement of the stewardship 
physician. A junior physician might be a less eﬀ  ective 
antimicrobial stewardship team member because of a 
perceived or real lack of knowledge and experience [48], 
but may be utilized because the ‘price is right’. In the 
survey by Pope and colleagues [41], personnel shortages 
(55%), ﬁ  nancial considerations (36%), and resistance from 
administration (14%) were frequent barriers to establishing 
antimicrobial stewardship programs. Oppo  si  tion from 
prescribing physicians was a barrier to establishing an 
antimicrobial stewardship program in about 27% of cases.
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consistently shown signiﬁ   cant improvement in anti-
micro  bial utilization, there are very few studies examin-
ing meaningful clinical outcome measures such as 
duration of hospitalization, mortality rates, or even 
quality indicators such as patient satisfaction. In the 
systematic review by the Cochrane Collaboration on 
antibiotic stewardship programs, clinical outcomes such 
as mortality and length of hospital stay were reported in 
only 15% of the studies [37]. In the 2008 survey by Pope 
and colleagues [41], only 25% of respondents reported 
clinical outcomes. Also, none of the studies report any 
signiﬁ   cant reduction in antimicrobial side eﬀ  ects as a 
result of these interventions.
Conclusion
Hospitals are increasingly implementing antimicrobial 
steward  ship programs in response to increasing anti-
micro  bial resistance (despite aggressive infection control 
practices), coupled with fewer novel antimicrobials and 
increasing antimicrobial costs. Th  ere is little question 
that antimicrobial use is causally related to antimicrobial 
resistance, and there is growing evidence that steward-
ship measures aimed at optimizing antimicrobial use can 
reduce antimicrobial resistance while reducing associated 
costs. Being major foci of antimicrobial resistance and 
the largest consumers of antimicrobials in most hospitals, 
ICUs can expect to beneﬁ   t most from antimicrobial 
stewardship programs.
Full implementation of antibiotic stewardship programs 
requires signiﬁ  cant investment, however. In the present 
economic climate, barriers to implementing such 
programs include personnel shortages, ﬁ  nancial cut  backs, 
and resistance from administration who are reluctant to 
assume economic risk. Focusing on patient safety 
initiatives and the beneﬁ   ts of cost savings and cost 
avoidance may enable hospital administrators to look 
upon antibiotic stewardship programs favourably [20]. 
Supplemental strategies such as consultations provided 
by specialists in infectious diseases might also be used in 
lieu of clinical decision support systems. Such expertise 
has been shown to improve antimicrobial use, shorten 
duration of mechanical ventilation and ICU stay, and to 
reduce in-hospital and ICU mortality [49], although it is 
unlikely that a clinical-decision support system would be 
entirely replaced. In addition to pre-authorization and/or 
audit-and-feedback approaches, ICUs should consider 
other strategies to improve antimicrobial utilization. In 
short, stewardship programs should be adapted accord-
ing to the individual needs of institutions, but should be 
adequately resourced to achieve their intended aims.
ICUs are complicated systems, and implementing a 
complex program into another complex structure raises 
the potential of unintended (and often unmeasured) 
adverse consequences. All ICUs should have an anti-
microbial stewardship program accompanied by a system 
to monitor clinically meaningful outcomes such as 
mortality and length of stay. Monitoring such outcomes 
presents an excellent opportunity for infection control 
and other patient quality and safety initiatives, whose 
aims include prevention of healthcare-associated infec-
tions and control of antibiotic-resistant organisms. In the 
absence of such monitoring, antimicrobial stewardship 
programs are nothing more than programs to reduce 
antimicrobial use with a largely unproven eﬀ  ect  on 
patient care. Close collaboration between critical care, 
infectious disease, infection control, medical informatics, 
microbiology, and pharmacy staﬀ    are needed for the 
success of an antimicrobial stewardship program. From 
our experience, leadership and a culture that embraces 
change is critical to implementation of a successful 
antimicrobial stewardship program.
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